Pozen shares fell 14 percent Friday after the pharmaceutical company posted a small first-quarter loss.
The Chapel Hill company previously was profitable for four consecutive quarters.
Pozen reported that it lost $27,358 in the first quarter, which amounted to zero cents per share, compared to net income of $2.9 million a year ago.
Revenue in the quarter totaled $4.4 million in royalties stemming from sales of Vimovo, its arthritis pain reliever. A year ago it reported $4.5 million in Vimovo royalties plus $3 million of the $15 million upfront licensing fee it received for Yosprala, its experimental cardiovascular drug.
Pozen shares closed Friday at $6.83, down $1.11. Its shares have fallen 15 percent for the year.